Chemotherapy News and Research

Latest Chemotherapy News and Research

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Early results from a large Phase-III trial suggest that adding bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim Perren from Leeds Teaching Hospitals NHS Trust, UK, reported findings from the international ICON7 trial, which included 1528 women with high-risk early or advanced stage epithelial ovarian cancer, primary peritoneal cancer or Fallopian tube cancer.

11 Oct 2010

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.

11 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending more advanced care to more patients. Clinicians at the hospital have used RapidArc® radiotherapy from Varian Medical Systems to treat patients for cancers of the nasopharynx, cervix, breast, and lung.

11 Oct 2010

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Health Robotics today announced that it recently signed exclusive distribution agreements for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies in seven new European countries with regional industry leaders Newico and Apta Medica, rapidly continuing on its worldwide quest to pervasively provide safe and cost-effective Intravenous (IV) Admixture Compounding Automation to hospitals all over the world.

11 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Genta announces EMA Orphan Drug designation for tesetaxel

Genta Incorporated today announced that tesetaxel, the leading oral taxane in clinical development, has been designated as an Orphan Drug by the European Medicines Agency for gastric cancer. The drug has previously received Orphan Drug designation by the U.S. Food and Drug Administration for both gastric cancer and melanoma, as well as Fast Track designation by FDA for gastric cancer.

11 Oct 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.

11 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Allos announces favorable survival data from FOLOTYN Phase 2b study

Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.

11 Oct 2010

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.

11 Oct 2010

TTF therapy with chemotherapy increases survival time in patients with non-small cell lung cancer

Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone.

11 Oct 2010

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

New natural dietary components inhibit breast cancer cells

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells.

11 Oct 2010

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics, Inc. and Millennium The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 58 relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients.

11 Oct 2010

Seattle Genetics reports SGN-75 phase I clinical trial data

Seattle Genetics, Inc. today reported data from a phase I clinical trial of SGN-75 in patients with non-Hodgkin lymphoma or renal cell carcinoma (RCC). Preliminary results demonstrate tolerability and antitumor activity, including two objective responses in the first 16 patients treated. Dose-escalation is continuing.

11 Oct 2010

Researchers identify factor that affects breast cancer patients' survival time in chemotherapy

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

11 Oct 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

Access highlights clinical benefits of MuGard at ESMO conference

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Genta announces EMA Orphan Drug designation for tesetaxel

AVEO presents tivozanib Phase 2 study results at ESMO Congress

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Allos announces favorable survival data from FOLOTYN Phase 2b study

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

TTF therapy with chemotherapy increases survival time in patients with non-small cell lung cancer

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

New natural dietary components inhibit breast cancer cells

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics reports SGN-75 phase I clinical trial data

Researchers identify factor that affects breast cancer patients' survival time in chemotherapy

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in